News
NEO
14.61
-1.55%
-0.23
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
NASDAQ · 1d ago
NeoGenomics price target raised to $16 from $11 at BofA
TipRanks · 4d ago
Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)
TipRanks · 4d ago
Weekly Report: what happened at NEO last week (0706-0710)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Argenx Se (ARGX)
TipRanks · 07/09 21:30
NeoGenomics (NEO) Stock Trades Up, Here Is Why
Barchart · 07/09 15:30
NeoGenomics Launches PTEN IHC CDx, Immunohistochemistry Companion Diagnostic Test Approved By FDA For Patients With Prostate Adenocarcinoma
Benzinga · 07/09 11:13
NEOGENOMICS LAUNCHES FDA-APPROVED PTEN IHC COMPANION DIAGNOSTIC FOR PROSTATE CANCER
Reuters · 07/09 11:05
Press Release: NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
Dow Jones · 07/07 11:06
NeoGenomics to report Q2 2026 results after U.S. market close
PUBT · 07/07 11:05
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
Barchart · 07/07 06:05
NeoGenomics on Track for Longest Winning Streak Since February 2019 -- Data Talk
Dow Jones · 07/06 15:32
Weekly Report: what happened at NEO last week (0629-0703)?
Weekly Report · 07/06 10:20
Biotech Is The Rate Cut Trade In Disguise
Seeking Alpha · 06/29 21:20
Weekly Report: what happened at NEO last week (0622-0626)?
Weekly Report · 06/29 10:15
The Disinflation Trade Has A New Address: Genomics
Seeking Alpha · 06/26 18:20
NeoGenomics director Carolyn S. Starrett files initial beneficial ownership statement
PUBT · 06/25 20:10
NeoGenomics Adds Data-Focused Independent Director to Board
TipRanks · 06/25 11:28
NeoGenomics appoints Flatiron Health ex-CEO Carolyn Starrett to board
PUBT · 06/25 11:05
NEOGENOMICS APPOINTS CAROLYN STARRETT TO ITS BOARD OF DIRECTORS
Reuters · 06/25 11:05
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.